Compare Globus Medical Inc. Class A Common Stock (GMED) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Charles Schwab Corporation Common Stock — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Charles Schwab Corporation Common Stock trades at $97.44 (market cap $165.91B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 16.2× Globus Medical Inc. Class A Common Stock's market cap, and Charles Schwab Corporation Common Stock pays a 1.33% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Charles Schwab Corporation Common Stock for 86 Days on average.
| GMED | SCHW | |
|---|---|---|
Market Cap | $10.25B | $165.91B |
Volume | 1,108,124 | 6,860,399 |
Sector | Health | Financials |
52-Week High | $96.82 | $113.65 |
52-Week Low | $58.33 | $85.35 |
Typical Hold Time | 0 Days | 86 Days |
Enterprise Value | $9.76B | $152.35B |
Dividend Yield | — | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Charles Schwab (SCHW) trades at $96.80, down 0.27% on the day, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported record quarterly revenue of $7.08 billion in Q3 2026 and has beaten earnings estimates for three consecutive quarters. Analyst consensus remains bullish with a $120.69 price target, representing 25% upside potential from current levels.
SCHW demonstrates robust financial health with 38.79% net margins and 22.45% ROE, though technical weakness and competitive pressures in brokerage services present near-term challenges. The stock offers attractive valuation at 17.48x P/E with strong earnings momentum, but investors should monitor interest rate sensitivity and market volatility impacts on trading volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
